Investigational Drug Information for MK-6482
✉ Email this page to a colleague
What is the drug development status for MK-6482?
MK-6482 is an investigational drug.
There have been 20 clinical trials for MK-6482.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 15th 2022.
The most common disease conditions in clinical trials are Carcinoma, Renal Cell, Carcinoma, and Neoplasms. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Peloton Therapeutics, Inc., and Eisai Inc.
There are five US patents protecting this investigational drug and fifty-six international patents.
Summary for MK-6482
| US Patents | 5 |
| International Patents | 56 |
| US Patent Applications | 33 |
| WIPO Patent Applications | 11 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 1 (2022-03-15) |
| Vendors | 32 |
Recent Clinical Trials for MK-6482
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024) | Merck Sharp & Dohme LLC | Phase 1/Phase 2 |
| A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal | Eisai Inc. | Phase 3 |
| A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal | Merck Sharp & Dohme LLC | Phase 3 |
Clinical Trial Summary for MK-6482
Top disease conditions for MK-6482
Top clinical trial sponsors for MK-6482
US Patents for MK-6482
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| MK-6482 | ⤷ Try a Trial | Compositions for use in treating pulmonary arterial hypertension | Peloton Therapeutics, Inc. (Dallas, TX) | ⤷ Try a Trial |
| MK-6482 | ⤷ Try a Trial | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (Dallas, TX) | ⤷ Try a Trial |
| MK-6482 | ⤷ Try a Trial | Combination therapy of a HIF-2-.alpha. inhibitor and an immunotherapeutic agent and uses thereof | Peloton Therapeutics, Inc. (Dallas, TX) | ⤷ Try a Trial |
| MK-6482 | ⤷ Try a Trial | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (Dallas, TX) | ⤷ Try a Trial |
| MK-6482 | ⤷ Try a Trial | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (Dallas, TX) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for MK-6482
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| MK-6482 | European Patent Office | EP3203991 | 2034-10-10 | ⤷ Try a Trial |
| MK-6482 | World Intellectual Property Organization (WIPO) | WO2016057242 | 2034-10-10 | ⤷ Try a Trial |
| MK-6482 | Argentina | AR097600 | 2033-09-09 | ⤷ Try a Trial |
| MK-6482 | Australia | AU2014318025 | 2033-09-09 | ⤷ Try a Trial |
| MK-6482 | Canada | CA2919397 | 2033-09-09 | ⤷ Try a Trial |
| MK-6482 | China | CN105530923 | 2033-09-09 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
